Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Total Current Liabilities (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Total Current Liabilities for 11 consecutive years, with $3.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities fell 3.32% to $3.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.3 million, a 3.32% decrease, with the full-year FY2024 number at $3.5 million, up 12.67% from a year prior.
  • Total Current Liabilities was $3.3 million for Q3 2025 at Marker Therapeutics, down from $4.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $13.5 million in Q2 2022 to a low of $2.0 million in Q2 2024.
  • A 5-year average of $5.6 million and a median of $4.1 million in 2021 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 138.07% in 2022, then crashed 78.32% in 2023.
  • Marker Therapeutics' Total Current Liabilities stood at $12.9 million in 2021, then plummeted by 39.68% to $7.8 million in 2022, then crashed by 60.49% to $3.1 million in 2023, then increased by 12.67% to $3.5 million in 2024, then decreased by 3.42% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Total Current Liabilities are $3.3 million (Q3 2025), $4.3 million (Q2 2025), and $2.5 million (Q1 2025).